You are here

Home » Content

FORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF ATENOLOL

Journal Name:

  • Advance Research in Pharmaceuticals and Biologicals

Publication Year:

  • 2011

Key Words:

Author Name
Abstract (2. Language): 
Transdermal drug delivery systems are becoming more popular in the field of modern pharmaceutics. The present study was carried out to develop matrix type transdermal patches containing Atenolol with different ratios of HPMC (hydroxyl propyl methyl cellulose) & EC (ethyl cellulose) by solvent casting method. Propylene glycol 3% is used as plasticizer & span 80 is used as permeation enhancer. The possible drugpolymer interactions were studied by FTIR studies. Formulated transdermal patches were evaluated with regard to physicochemical characteristics, in-vitro permeation studies and stability studies. All the prepared formulations showed good physical stability. The in-vitro permeation studies were performed using Franz diffusion cell. Out of all the formulated patches HF4 & HE3 showed good permeation in 24 hrs. So these two formulations were selected as best formulations.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastrmx_160852_1_pp_109-119.pdf
  • 2
109-119
  • English

REFERENCES

References: 

1. D. M. Brahmankar & S. B. Jaiswal.
Biopharmaceutics and Pharmacokinetics,
Vallabh Prakashan, Delhi, II ed. 2009, pp.
495-501.
2. S. P. Vyas, R. K. Khar. Controlled Drug
Delivery Concepts and Advances, Vallabh
Prakashan, Delhi, I ed. 2002. Reprint 2005,
pp. 411-447.
3. G. Chopda. Transdermal delivery system, a
review, Pharmainfo.net. 12th January 2006,
pp. 2-11.
4. P. B. Patel, A. Chaudhary, and G. A.
Gupta. Recent progress in active
transdermal drug delivery technologies,
Pharmainfo.net. 10th June 2006, pp. 3-12.
Mohd. Amjad et .al., ARPB, 2011; Vol 1(2) ISSN 2250 - 0744
(Research Article)
www.arpb.info Page 119
5. M. E., Aulton. Pharmaceutics, The science
of Dosage form Design, Churchill
Livingstone, Elsevier, ed. II 2002, reprint
2004, pp. 499-533.
6. Y. W. Chein. Novel drug delivery systems,
Marcel Dekker, New York, ed. II, revised
and expanded, pp. 301-380.
7. Government of India ministry of health and
family welfare, Indian Pharmacopoeia,
published by the controller of publications,
Delhi, Vol-I, 1996, pp. 72-74.
8. B. G. Katzung, S. B. Masters & A. J.
Trevor. The basic and clinical
pharmacology, TATA McGraw-HILL,
New Delhi, 11th ed. 2009, reprint 2010. pp.
176.
9. Goodman & Gillman’s, The
Pharmacological Basics of Therapeutics,
McGrawHill, New Delhi, 11th ed. pp. 845-
868.
10. Rang and Dale’s Pharmacology, Churchill
Livingstone Elsevier, 6th ed. Reprint 2008,
pp. 298-320.
11. B. G. Katzung, S. B. Masters & A. J.
Trevor. The basic and clinical
pharmacology, TATA McGraw-Hill, New
Delhi, 11th ed. 2009, reprint 2010. pp. 167-
189.
12. Government of India ministry of health and
family welfare, Indian Pharmacopoeia,
published by controller of publications,
Delhi. Vol-II, 1996, pp. A-145.
13. S. Mondol, J. Thimmasetty, G.N. Ratan,
B.H. Kilarimath. Formulation and
Evaluation of Carvedilol transdermal
patches, Int. Res. J Pharmacy 2 (1): 237-
248 (2011).
14. J. R. D. Gupta, R. Irchhiya, N. Garud, P.
Tripathi, P. Dubey, and J. R. Patel.
Formulation and evaluation of matrix type
transdermal patches of Glibenclamide, Int.
J Pharm. Sci and Drug Res. 46-50 (2009).
15. S. P. Vyas, R. K. Khar. Controlled Drug
Delivery concepts and advances, Vallabh
Prakashan, ed. I 2002. Reprint 2005, pp.
440-446.
16. N. K. Jain. Controlled and Novel Drug
Delivery, CBS Publishers & Distributors
Pvt. Ltd, ed. I 1997, reprint 2011, pp. 118-
127.

Thank you for copying data from http://www.arastirmax.com